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Abstract
Purpose Hormonal changes after menopause can cause
dyslipidemia by the cessation of endogenous estrogen. We
analyzed the lipid profile of the Korean healthy meno-
pausal women according to the use of hormone replace-
ment therapy (HRT).
Methods Data obtained from the Korea National Health
and Nutrition Examination Survey (KNHANES)
2010–2012 were analyzed. The study included 428 healthy
postmenopausal women with HRT (HRT group) and 1804
healthy postmenopausal women without HRT (NHRT
group).
Results After adjustment for confounding factors, total
cholesterol (TC) and low-density lipoprotein (LDL) were
lower in the HRT group than in the NHRT group (TC:
200.1 ± 2.0 vs. 204.9 ± 1.1, P = 0.04; LDL: 120.3 ± 1.0
vs. 124.5 ± 1.0 mg/ml, P = 0.033). Triglycerides (TG)
were lower in the HRT group than in the NHRT group
[106.8, (95 % CI 99.8–114.3) vs. 115.1 (95 % CI
111.8–118.5), P = 0.04]. Non-high-density lipoprotein
(HDL) was lower in the HRT group than in the NHRT
group (145.4 ± 1.9 vs. 151.2 ± 1.0 mg/ml, P = 0.008).
Patients with HRT were lower in the LDL cholesterol level
(OR 0.601, 95 % CI 0.397–0.917, P = 0.018), the total
cholesterol to high-density lipoprotein ratio (OR 0.787,
95 % CI 0.617–0.997, P = 0.016), and the non-HDL level
(OR 0.68, 95 % CI 0.509–0.907, P = 0.009).
Conclusion The results of this study suggest that the use
of HRT may have a positive effect on dyslipidemia in
postmenopausal women.
Keywords Hormone replacement therapy (HRT) 
Dyslipidemia  Menopause  Korean National Health and
Nutrition Survey (KNHANES)
Introduction
Coronary heart disease (CHD) is a fatal disease in both
men and women, increasing average life span and obese
people’s attention to CHD. The relative risk of CHD-
related death is increased in men (2.5–4.5) compared to
women at a younger age [1]. As for age-specific inci-
dence, the number of CHD events in men equals to that
in women 10 years older. The male/female mortality
ratio is 5:1 for those aged 35–44 years, and 1.5:1 for
those aged over 75 years [2]. Gender differences seem to
delay the risk of CHD by 10 years, a time shift usually
attributed to female sex hormones. It is postulated that
changes in endogenous hormones during or after meno-
pause transition explain most of the gender differences in
CHD [3].
Dyslipidemia is an important risk factor for CHD, which
can be corrected and prevented. It has been defined as an
elevation in total cholesterol (TC), triglycerides (TG), and
low-density lipoprotein cholesterol (LDL), or a reduction
in high-density lipoprotein cholesterol (HDL) [4]. Non-
HDL as calculated by subtracting the HDL level from the
TC level, and the lipid-related ratio have been proposed to
be predictive factors for CHD [5, 6].
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Hormone replacement therapy (HRT) is widely used to
treat menopausal symptoms and prevent osteoporosis,
cardiovascular disease, and dementia [7–9]. The regimen is
estrogen alone in women undergoing hysterectomy, and
estrogen combined with progestin reduces endometrial
hyperplasia or cancer [10].
Some studies have found that the use of HRT is asso-
ciated with an improvement in the lipid profile in healthy
postmenopausal women, whereas others have found no
beneficial effects [11–14]. Most of the previous studies on
the relationship between HRT and lipid variables have
been conducted in Western in women [5, 10, 15], while few
studies have been undertaken in Asian women. This cross-
sectional study was based on data from the Korea National
Health and Nutrition Examination Survey (KNHANES)
2010–2012 conducted by the Korea Centers for Disease
Control and Prevention. The purpose of this study was to
evaluate the relationship between the use of HRT and lipid
metabolism in healthy postmenopausal Korean women.
Materials and methods
Study subjects
This study included 428 healthy postmenopausal women
with HRT (HRT group) and 1804 healthy postmenopausal
women without HRT (NHRT group). It was designed to
evaluate nationwide health and nutrition status, and
comprised a health interviews, nutritional assessment, and
health examination. The NHRT group consisted of
women ranging from 38 to 64 years of age, who were
aged between 30 and 60 years at menopause. The HRT
group consisted of women ranging from 43 to 64 years of
age, who were aged between 15 and 58 years at meno-
pause. The HRT group included women who were
receiving estrogen-alone oral therapy, combined estrogen/
progestogen derivatives, or non-androgenic proges-
terone/transdermal estrogen therapy for at least 6 months.
The duration of HRT ranged from 0.5 to 37 years. In this
study, we used the following questions: (1) Have you
taken hormone preparations for more than 6 months? (2)
How long have you taken hormone preparations? (3) At
what age did you start to take hormone preparations?
Menopause was defined as a menstruation-free period of
at least 12 months.
Questionnaires were used to collect a detailed history,
which included age at menarche and menopause, the his-
tory of operation, pregnancy, parity, the use of oral con-
traceptives, the use of HRT as well as the duration of HRT
and life-style variables.
The survey was reviewed and approved by the Institu-
tional Review Board of the Seoul St. Mary’s hospital, The
Catholic University of Korea (KC15EISI0188). All par-
ticipants provided written informed consent.
Life-style variables and anthropometric
measurements
Alcohol consumption, smoking status, and physical activity
were investigated using the self-reported questionnaire.
Based on the amount of alcohol consumed per day up to
1 month before the interview, subjects who had consumed
C30 g/day of alcohol were classified as heavy drinkers
[16]. Physical activity was assessed using a short form of
the International Physical Activity Questionnaire modified
for the Korean population [17]. Subjects who exercised
moderately for over 30 min per session more than 5 times
per week, or those who exercised vigorously for over
20 min per session more than 3 times per week were
defined as regular physical exercisers.
Height and body weight were measured and rounded to
the nearest 0.1 cm and 0.1 kg, respectively. Body mass
index (BMI) was calculated using the formula: body
weight (kg)/height2 (m2). Waist circumference (WC) was
measured at the midpoint between the lower costal margin
and the iliac crest during expiration. Blood pressure (BP)
was measured in the sitting position using a standard
mercury sphygmomanometer 3 times at 5-min intervals.
The average of the second and third measurements was
used in the analyses.
Biochemical measurements
Blood samples were obtained in the morning following
C8 h of fasting. The samples were properly processed,
immediately refrigerated, and transported via cold storage
units to the Central Testing Institute in Seoul, Korea, and
analyzed within 24 h. The conventional parameters of
dyslipidemia were defined according to the criteria of the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP/ATP III) [4, 18]. Serum TC, TG, and HDL
were measured by means of a Hitachi Automatic Analyzer
7600 (Hitachi, Tokyo, Japan) using enzymatic methods
with commercially available kits (Daiichi, Tokyo, Japan).
The LDL level was calculated using Friedewald’s formula
in subjects with a TG of B400 mg/dl, and it was measured
directly with commercially kits (Cholestest LDL; Sekisui
Medical, Tokyo, Japan) when the TG level was[400 mg/
dl. The NHDL level was calculated as TC minus HDL, and
high NHDL levels were defined as C160 mg/dl [19].
Dyslipidemia was defined as the presence of C1 or more
of the following abnormal lipid profiles. Hypercholes-
terolemia was defined as (1) a TC of C240 mg/dl in fasting
blood tests, (2) the use of a lipid-lowering agent, and (3)
physician-diagnosed dyslipidemia. Hypo-HDL
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cholesterolemia was defined as HDL \40 mg/dl. Hyper-
LDL cholesterolemia was defined as (1) LDL[160 mg/dl,
(2) the use of a lipid-lowering agent or (3) physician-di-
agnosed dyslipidemia. Hypertriglyceridemia was defined
as a TG of C200 mg/dl. In addition, high TC to HDL ratio
(TC/HDL[5), TG to HDL ratio ([3.8), and LDL to HDL
ratios ([2) were considered dyslipidemia [20–22].
Statistical analysis
All statistical analyses were performed using the SAS
version 9.2 (SAS institute, Cary, NC, USA) in a manner
reflecting sampling weights and providing nationally rep-
resentative estimates. A P value of\0.05 was considered
statistically significant. The independent t test or v2 test
was used for the assessment of differences in clinical and
biochemical characteristics between the HRT and NHRT
groups. Analysis of covariance (ANCOVA) was used to
determine the adjusted mean ± standard error (SE) of each
lipid variables according to use of HRT. Age- and multi-
variate-adjusted logistic regression analyses were con-
ducted to evaluate the relationship between dyslipidemia
variables according to the use of HRT, and odds ratios
(ORs) and 95 % confidence intervals (CIs) were estimated.
Age, BMI, alcohol consumption, smoking, exercise,
hypertension, and diabetic mellitus in subjects were con-
sidered confounding factors in multivariate analyses.
Results
Table 1 shows the baseline characteristics of the study
subjects. The mean ± SEM duration of the use of HRT
was 6.2 ± 0.3 years. As for anthropometric factors, BMI
and WC were higher in the NHRT group than in HRT
group (BMI: 24.3 ± 0.1 vs. 23.8 ± 0.2 kg/m2, P = 0.007;
Table 1 Characteristics of the
study subjects
NHRT (n = 1804) HRT (n = 423) P valueb
Age, years 56.2 ± 0.1 56.3 ± 0.3 0.829
BMI, kg/m2 24.3 ± 0.1 23.8 ± 0.2 0.007
WC, cm 81.9 ± 0.3 79.5 ± 0.5 \0.001
Systolic blood pressure, mmHg 123.3 ± 0.6 120.3 ± 1.1 0.017
Diastolic blood pressure, mmHg 77.8 ± 0.3 76 ± 0.6 0.007
Fasting glucose, mg/ml 100 ± 0.8 95.6 ± 0.9 \0.001
Total cholesterol (TC), mg/ml 205.8 ± 1.1 199.4 ± 2.0 0.007
High-density lipoprotein (HDL), mg/ml 53.9 ± 0.3 55.4 ± 0.9 0.132
Low-density lipoprotein (LDL), mg/ml 125.1 ± 1.0 119.5 ± 1.8 0.006
TC/HDL 4.0 ± 0.0 3.8 ± 0.1 0.009
LDL/HDL 2.4 ± 0.0 2.3 ± 0.0 0.01
Non-HDL 152 ± 1.1 144 ± 1.9 \0.001
Triglycerides (TG)a, mg/ml 115.9 (112.2, 119.7) 105.0 (97.8, 112.6) 0.013
TG/HDLa 2.2 (2.1, 2.3) 2.0 (1.8, 2.1) 0.019
Delivery history 0.114
None 2.9 (0.5) 4.1 (1.2)
1–2 53.1 (1.6) 59.7 (3.0)
3–4 39.1 (1.5) 32.8 (3.1)
C5 5.0 (0.5) 3.4 (1.2)
Smoking history (ever) 5.8 (0.8) 7.8 (1.8) 0.259
Alcohol drinking (within a month) 32.7 (1.4) 33.1 (2.8) 0.897
Exerciser 17.9 (1.2) 18.8 (2.2) 0.718
Rural resident 25.7 (2.4) 18.1 (3) 0.022
Spouse 83.4 (1.1) 84.4 (2.2) 0.694
Lipid-lowering agent 10.7 (0.9) 16.3 (2.2) 0.01
Diabetes mellitus 18.7 (1.2) 12.3 (2.5) 0.048
Hypertension 17.9 (1.3) 17.8 (1.5) 0.97
Values represent means ± SEMs or proportions (SEs)
a Log transformation was performed to obtain P values, and values represent geometric means (95 % CI)
b Obtained by the t test or the v2 test
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WC: 81.9 ± 0.3 vs. 79.5 ± 0.5 cm, P\ 0.001). Systolic
and diastolic blood pressures were also higher in the NHRT
group than in the HRT group (systolic blood pressure:
123.3 ± 0.6 vs. 120.3 ± 1.1 mmHg, P = 0.017; diastolic
blood pressure: 77.8 ± 0.3 vs. 76.0 ± 0.6 mmHg,
P = 0.007). As for lipid variables, TC, LDL, TG, and non-
HDL were lower in the HRT group than in the NHRT
group [TC: 199.4 ± 2.0 vs. 205.8 ± 1.1 mg/ml,
P = 0.007; LDL: 119.5 ± 1.8 vs. 125.1 ± 1.0 mg/ml,
P = 0.006; TG: 105.0 (95 % CI 97.8–112.6) vs. 115.9
(95 % CI 112.2–119.7), P = 0.013; non-HDL:
144.0 ± 1.9 vs. 152.0 ± 1.1 mg/ml, P\ 0.001]. The TC/
HDL ratio (3.8 ± 0.1 vs. 4.0 ± 0.0, P = 0.009), LDL/
HDL ratio (2.3 ± 0.0 vs. 2.4 ± 0.0, P = 0.01), and TG/
HDL ratio [2.0 (95 % CI 1.8–2.1) vs. 2.2 (95 % CI
2.1–2.3), P = 0.019] were lower in the HRT group than in
the NHRT group. The incidence of CHD and stroke is
presented in Table 2. The incidence of CHD was higher in
the NHRT group than in the HRT group, but it was not
statistically significant (P = 0.11).
Figure 1 illustrates the distributions of the levels of lipid
variables in quartiles in the HRT group indicating that the
proportion of women with low TG levels was higher in the
HRT group (P for trend = 0.007). In particular, such
trends were noted in the TG/HD ratio (P for
trend = 0.015), the TC/HDL ratio (P for trend = 0.003),
the LDL/HDL ratio (P for trend = 0.001), and the NHDL
level (P for trend = 0.009).
Table 3 shows changes in the levels of lipid variables
according to the duration of HRT. TG, the TG/HDL ratio,
Non-HDL, and the LDL/HDL ratio were proportionately
decreased with increasing duration of HRT. In addition, the
lowest values were noted when the duration of HRT was
greater than 5 years.
Table 2 Incidence of coronary
heart disease and stroke
between NHRT and HRT group
NHRT HRT P value
CHD 3.3 (0.5) 1.4 (0.8) 0.10
Stroke 0.7 (0.2) 0.9 (0.5) 0.68
Cardiovascular disease (CHD ? stroke) 4 (0.6) 2.3 (0.9) 0.18
Valuables mean percentage (SE)
CHD coronary heart disease
TC TG* HDL LDL TG/HDL† TC/HDL‡ LDL/HDL§ Non HDL¶
0-25% 25-50% 50-75% 75-100%
D
istribution levels 
Fig. 1 The distribution of the
levels of lipid variables in
quartiles in the HRT group.
*P for trend 0.007, P for trend
0.015, P for trend 0.003, §P for
trend 0.001, }P for trend 0.009
Table 3 Time-dependent effects on lipid profile of HRT
NHRT 0.5 yearB,[3 years 3 yearsB and[5 years 5 yearsB P value
TC 205.4 ± 1.1 199.2 ± 4.1 196.2 ± 4.2 200.7 ± 2.9 0.06
TGa 115.6 (112.2, 119) 115.7 (100.7, 132.9) 104.5 (87.6, 124.7) 103.9 (96, 112.5) 0.06
HDL 53.8 ± 0.3 54 ± 1.8 53.5 ± 1.7 55.9 ± 1.1 0.35
LDL 124.8 ± 1 118.3 ± 3.8 117.8 ± 4.2 120.6 ± 2.5 0.07
TG/HDLa 2.2 (2.1,2.3) 2.2 (1.9, 2.6) 2 (1.6, 2.5) 1.9 (1.7, 2.1) 0.08
TC/HDL 4.0 ± 0.0 3.9 ± 0.1 3.9 ± 0.2 3.8 ± 0.1 0.06
Non-HDL 2.4 ± 0.0 2.3 ± 0.1 2.4 ± 0.2 2.2 ± 0.1 0.02
LDL/HDL 151.6 ± 1.0 145.2 ± 4.0 142.7 ± 4.2 144.8 ± 2.6 0.01
Values represent means ± SEMs or proportions (SEs)
a Geometric mean (95 % CI)
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Table 4 shows the mean levels of lipid variables in both
groups according to the use of HRT after adjustment. In
Model 3, after adjustment for age, BMI, smoking, drinking,
exercise, DM, hypertension, and the use of lipid-lowering
agents, TC, TG, LDL, and non-HDL were significantly
lower in the HRT group than in the non-HRT group (TC:
204.9 ± 1.1 vs. 201.1 ± 2.0, P = 0.04; TG: 115.1 vs.
106.8 P = 0.04; LDL: 124.5 ± 1.0 vs. 120.3 ± 1.7,
P = 0.033; non-HDL: 151.2 ± 1.0 vs. 145.4 ± 1.9,
P = 0.008).
Table 5 presents adjusted odds ratios in the HRT and
non-HRT groups according to the diagnostic criteria for
dyslipidemia. In Model 3, after adjustment for age, BMI,
drinking, DM, hypertension, and medication, the HRT
group showed a low hyper-LDL-cholesterolemia (OR
0.601, 95 % CI 0.394–0.917, P = 0.018), a low TC/HDL
ratio (OR 0.787, 95 % CI 0.617–0.997, P = 0.016), and a
low non-HDL level (OR 0.68, 95 % CI 0.509–0.907,
P = 0.009). In Model 4, after adjustment for age, BMI,
drinking, DM, hypertension, medication, triglyceride, and
cholesterol, the HRT group showed a low hyper-LDL
cholesterolemia (OR 0.61, 95 % CI 0.4–0.92, P = 0.021)
and a low non-HDL level (OR 0.725, 95 % CI
0.539–0.977, P = 0.034).
There were significant differences in the levels of lipid
variables between the NHRT and HRT groups according to
the use of lipid-lowering agents (Table 1, P = 0.01). Table 6
shows the adjusted odds ratios in the NHRT and HRT groups
according to the use of lipid-lowering agents. In women with
no use of lipid-lowering agents, hyper-LDL cholesterolemia
(OR 0.524, 95 % CI 0.322–0.853, P = 0.009), the TG/HDL
ratio (OR 0.671, 95 % CI 0.454–0.992, P = 0.04), and the
non-HDL level (OR0.71, 95 %CI 0.51–0.97,P = 0.03)were
significantly lower in theHRTgroup than in theNHRTgroup.
In women with use of lipid-lowering agents, hypercholes-
terolemia (OR 4.63, 95 % CI 0.86–24.87, P = 0.07) and
hyper-LDL cholesterolemia (OR 5.33, 95 % CI 0.99–28.48,
P = 0.05) were higher in the HRT group than in the NHRT
group, but the difference was not statistically significant.
Figure 2 shows the distribution of dyslipidemia
according to the use of HRT. It shows statistically signif-
icant differences in NHDL, the TC/HDL ratio, and the TG/
HDL ratio between the 2 groups.
Discussion
Hormone replacement therapy is widely used in meno-
pausal women to treat menopausal vasomotor symptoms
and prevent osteoporosis, cardiovascular disease, and
dementia. Estrogen also affects vascular tone and blood
flow as well as lipid metabolism [7, 23, 24]. Previous
studies have been undertaken to determine the effects of
the loss of endogenous sex hormones on lipid and
lipoprotein metabolism.
Table 4 Differences in the levels of lipid variables according to the use of hormonal agents
Model 1b Model 2c Model 3d
NHRT HRT P value NHRT HRT P value NHRT HRT P value














HDL 53.8 ± 0.3 54.9 ± 0.9 0.237 53.8 ± 0.3 54.9 ± 0.9 0.259 53.7 ± 0.3 54.7 ± 0.9 0.302
LDL 124.9 ± 1 119.4 ± 1.8 0.009 124.8 ± 1 119.2 ± 1.8 0.008 124.5 ± 1 120.3 ± 1.7 0.033
TC/
HDL
4.0 ± 0.0 3.8 ± 0.1 0.03 4.0 ± 0.0 3.8 ± 0.1 0.028 4.0 ± 0.0 3.9 ± 0.1 0.089
LDL/
HDL
2.4 ± 0.0 2.3 ± 0.0 0.022 2.4 ± 0.0 2.3 ± 0.0 0.022 2.4 ± 0.0 2.3 ± 0.0 0.08
Non-
HDL
151.6 ± 1.0 144.5 ± 1.9 0.002 151.5 ± 1.0 144.2 ± 1.9 0.001 151.2 ± 1.0 145.4 ± 1.9 0.008
TG/
HDLa
2.2 (2.1, 2.3) 2.0 (1.8, 2.2) 0.069 2.2 (2.1, 2.3) 2.0 (1.8, 2.2) 0.059 2.2 (2.1, 2.3) 2.0 (1.8, 2.2) 0.073
Values expressed as means ± SEMs. P value was obtained by ANCOVA
NHRT group without hormone replacement therapy, HRT group with hormone replacement therapy, TC total cholesterol, TG triglyceride, HDL
high-density lipoprotein, LDL low-density lipoprotein, non-HDL non-high-density lipoprotein
a Values expressed as geometric means (95 % CI)
b Adjusted for age and body mass index (BMI)
c Adjusted for age, BMI, smoking, drinking, and exercise
d Adjusted for age, BMI, smoking, drinking, exercise, diabetes mellitus, hypertension, and medication
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The postmenopausal estrogen/progestin intervention
(PEPI) Trial has indicated that HRT increases HDL,
decreases LDL, but does not affect the occurrence of CHD
[25]. Mathew et al. [26] have demonstrated that only total
cholesterol, LDL, and apolipoprotein-B increase within the
1-year interval before and after the final menstrual period
[26]. Nerbrand et al. [15] conducted the Women’s Health
in the Lund Area (WHILA) study in 6908 women grouped
into premenopausal women, postmenopausal women
without HRT, and postmenopausal women with HRT, and
examined differences in serum lipid variables between the
groups. They reported that cessation of endogenous sex
hormones after menopause increases TG and TC, and
decreases HDL, which can be reversed by the use of HRT.
Crespo et al. [5] examined the relationship of HRT with
fasting glucose and lipid variables in diabetic and nondia-
betic postmenopausal women. They reported that among
diabetic women current users of HRT have significantly
different lipid and glucose levels than never user HRT for
the following variables: TC (225 vs 241 mg/dl), non-HDL
(169 vs 188 mg/dl), and glucose (112 vs 154 mg/dl).
Likewise, our study revealed that TC, LDL, non-HDL, and
TG levels were lowered. However, the HDL level was not
affected by HRT, while it was increased by HRT in several
previous studies [10, 15, 27]. The use of HRT increases the
HDL level, and the magnitude of increase appears to be
related to the type and dosage of estrogen as well as the
route of administration, but progestin has a negative effect
on HDL [10].
When we analyze the hormonal effect on lipid variables,
we must consider aging. Aging itself decreases HDL and
increases TC, LDL, and TG [28]. Hall et al. [29] followed
up 143 women for 5 years through menopause with annual
measurements. They reported that transition to menopause
is accompanied by increases in serum TC and TG, which is
consistent with our results. Some investigators have
reported the time course of changes in the lipid profile.
Kika et al. [27] have demonstrated that HDL is signifi-
cantly increased 12 months after the start of HRT and that
at the 3 months later in HRT group, TC and LDL levels are
decreased, while the TG level is increased 3 months after
the start of HRT. Also Park et al. [30] have documented
that 12 weeks after HRT, HDL and TG levels are increased
by 12 % and TG 20 %, respectively, while LDL and
lipoprotein(a) levels are decreased by 9 and 36 %,
respectively, in postmenopausal patients with end-stage
renal disease. Kim et al. [31] reported the effects of HRT
on lipid variables in postmenopausal women according to
various progestogens and duration of therapy. HDL was
more increased in subjects on estrogen-alone therapy than
Table 5 Adjusted odds ratios according to the criteria for dyslipidemia in the HRT and NHRT groups
Model 1a OR
(95 % CI)
P value Model 2b OR
(95 % CI)
P value Model 3c OR
(95 % CI)













































































OR odds ratio, CI confidence interval, TC total cholesterol, TG triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, Non-
HDL non-high-density lipoprotein
a Adjusted for age and body mass index (BMI)
b Adjusted for age, BMI, smoking, drinking, and exercise
c Adjusted for age, BMI, smoking drinking, exercise, diabetes mellitus, hypertension, and medication
d Adjusted for age, BMI, smoking, exercise, diabetes mellitus, hypertension, medication, total cholesterol and triglyceride
e In model 4, adjusted for triglyceride
f In model 4, adjusted for cholesterol
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in those on other therapies (16.5 vs. 10.8–13.8 %,
P\ 0.001), which may have been attributed to the
androgenic effects of progestogens [8, 9]. A combination of
estrogen and medroxyprogesterone significantly decreased
the levels of LDL (17.6 vs. 10.9–13.7 %, P\ 0.01) and
TG (32.6 vs. 0–20.7 %, P\ 0.001). The levels of lipid
variables were changed in a time-dependent manner.
This study has some limitations at this point. First, this is
a cross-sectional study, and thus it did not analyze the
changing patterns of lipid variables according to the use of
HRT. Second, since this study did not categorize hormonal
agents, it did not present differences according to the dif-
ferent types of the agents. Since this is a cross-sectional
study using a questionnaire that included the questions
about the use of HRT, but the types of hormonal agents, it
is difficult to evaluate the differences in the levels of lipid
variables according to the types of the agents. However,
this study has clinical implications in that it is the first
large-scale study of Korean healthy menopausal women.
Further prospective studies on the effects of HRT with
various combinations of sex hormones and duration of
treatment on changes in lipid variables would be warranted.
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